Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2010Immunology Endocrine & Metabolic Agents - Medicinal Chemistry

Preclinical data suggests myostatin inhibition ameliorates pathology, increases muscle mass and strength, and improves muscle quality, though clinical experience remains limited.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Do myostatin inhibitors improve muscle mass and strength in individuals with neuromuscular diseases?

Population

Individuals with neuromuscular diseases and preclinical models (e.g., mouse models of muscular dystrophies)

Design

Review

Authors

KWKathryn R. Wagner

Discussion

Loading...

Member takes

Overview

Remains investigational in neuromuscular disease; leaves open clinical translation of preclinical benefits pending trials.

Structured PICO

Do myostatin inhibitors improve muscle mass and strength in individuals with neuromuscular diseases?

P
Population
Individuals with neuromuscular diseases and preclinical models (e.g., mouse models of muscular dystrophies)
I
Intervention
Myostatin inhibitors

Myostatin inhibitors show promise in preclinical models for treating neuromuscular diseases by increasing muscle mass and quality, but clinical trials are needed to determine safety and efficacy.

Limitations

  • Potential negative consequences of long term inhibition are unknown but may include replicative senescence of muscle progenitor cells, tendon shortening and off-target side effects

Cite This Study

Kathryn R. Wagner (2010) studied this question.

synapsesocial.com/papers/6a90ebe2e55c7a42f270fd83https://doi.org/10.2174/187152210793663775
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Myostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders?2020 · 85 citations
  2. 2Myostatin inhibition promotes fast fibre hypertrophy but causes loss of AMP‐activated protein kinase signalling and poor exercise tolerance in a model of limb‐girdle muscular dystrophy R1/2A2020 · 14 citations
  3. 3Genetic and Pharmacologic Inhibition of Myostatin Restores Muscle Mass in a Dynamin 2 ‐Related Centronuclear Myopathy Mouse Model2026
  4. 4Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child2004 · 1,403 citations
  5. 5Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches2017 · 139 citations